Tobramycin: A review of therapeutic uses and dosing schedules

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 7, 1998, Pages 420-453

  Lode, Hartmut ^a  

^a Hospital Zehlendorf   (Germany)

Author keywords

Aminoglycosides; Clinical outcomes; Multiple daily dosing; Once daily dosing; Tobramycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; NETILMICIN; TOBRAMYCIN;

COST CONTROL; DOSE RESPONSE; DRUG CHOICE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESEARCH; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT OUTCOME;

EID: 0031831371     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85082-0     Document Type: Article

References (151)

1. Higgins CE, Kastner RE. Nebramycin, a new broad spectrum antibiotic complex II. Description of Streptomyces tenebrarius. Antimicrob Agents Chemother. 1967;7:324-331.
2. Preston DA, Wick WE. Preclinical assessment of the antibacterial activity of nebramycin factor 6. Antimicrob Agents Chemother. 1970;10:322-327.
3. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657-662.
4. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteraemia. J Infect Dis. 1984;149:443-448.
5. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
6. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis. 1990;74(Suppl):63-70.
7. Wiedemann B, Grimm H. Susceptibility to antibiotics: Species incidence and trends. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th ed. Baltimore: Williams & Wilkins; 1996:900-1168.
8. Neu HC, Chin NX, Novelli A. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1988; 32:1666-1675.
9. Espinoza AM, Chin N-X, Novelli A, Neu HC. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988;32:663-670.
10. Zurenko GE, Yagi BH, Vavra JJ, Wentworth BB. In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog. Antimicrob Agents Chemother. 1988;32:216-223.
11. Chin N-X, Neu HC. Tigemonam, an oral monobactam. Antimicrob Agents Chemother. 1988;32:84-91.
12. Gobernado M, Canton E. Comparative in vitro activity of temocillin. Drugs. 1985; 29(Suppl 5):S24-S31.
13. Chamberland S, L'Ecuyer J, Lessard C, et al. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. Clin Infect Dis. 1992;15:615-628.
14. Guimaraes MA, Sage R, Noone P. The comparative activity of eleven aminocyclitol antibiotics against 773 aerobic gram-negative rods and staphylococci isolated from infected hospitalized patients. J Antimicrob Chemother. 1985;16:555-561.
15. Clarke AM, Zemcov SJ. Comparative in vitro activity of lomefloxacin: A new difluoroquinolone. Eur J Clin Microbiol Infect Dis. 1989;8:164-168.
16. Wise R, Ashby JP, Andrews JM. In vitro activity of PD 127,391 an enhanced-spectrum quinolone. Antimicrob Agents Chemother. 1988;32:1251-1256.
17. Norrby SR, Jonsson M. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother. 1988;32:1278-1281.
18. Rylander M, Gezelius L, Norrby SR. Comparative in-vitro activity of tigemonam, a new monobactam. J Antimicrob Chemother. 1988;22:307-313.
19. Smith RP, Baltch AL, Hammer MC, Conroy JV. In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob Agents Chemother. 1988;32:1450-1455.
20. Smith JA, Henry DA. Comparison of bactericidal activity of selected β-lactam antimicrobials against Pseudomonas aeruginosa. J Antimicrob Chemother. 1988;22:849-855.
21. Klastersky J, Cappel R, Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972;2:470-475.
22. Klastersky J, Meunier-Carpentier F, Prevost J-M. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci. 1977;273:157-167.
23. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24:45-54.
24. Lau WK, Young LS, Black RE, et al. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients. A randomized prospective trial. Am J Med. 1977;62:959-966.
25. Gerber AU, Vastola AP, Brandel J, Craig WA. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis. 1982;146:691-697.
26. Michéa-Hamzehpour M, Pechère JC, Marchou B, Auckenthaler R. Combination therapy: A way to limit emergence of resistance? Am J Med. 1986;80:138-142.
27. Pechère JC, Marchou B, Michéa-Hamzehpour M, Auckenthaler R. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother. 1986;17(Suppl A):S11-S18.
28. Stillwell PC, Kearns GL, Jacobs RF. Endotracheal tobramycin in gram-negative pneumonitis. Drug Intell Clin Pharm. 1988;22:577-581.
29. Cunha BA. Aminoglycosides: Current role in antimicrobial therapy. Pharmacotherapy. 1988;8:334-350.
30. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9-22.
31. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352-357.
32. Smith CR, Moore RD, Lietman PS. Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis. 1986;8:308-313.
33. Sande MA, Mandell GL. Antimicrobial agents: The aminoglycosides. In: Gilman AG, Rail TW, Nies AF, Taylor P, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw-Hill; 1993:1098-1116.
34. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:279-306.
35. Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167:173-179.
36. Dew RB, Susla GM. Once daily aminoglycoside treatment. Infect Dis Clin Pract. 1996; 5:12-24.
37. Neu HC, Bendush CL. Ototoxicity of tobramycin: A clinical overview. J Infect Dis. 1976;134(Suppl):S206-S218.
38. Lerner SA, Schmitt BA, Seligsohn MD, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med. 1986;80:98-104.
39. Baarsma EA, Rijntjes E. Vestibulo-toxicity of tobramycin. J Laryngol Otol. 1979;93: 725-727.
40. Yamane H, Nakagawa T, Iguchi H, et al. In vivo regeneration of vestibular hair cells of guinea pig. Acta Oto-Laryngol Suppl. 1995;520:174-177.
41. Janas JD, Cotanche DA, Rubel EW. Avian cochlear hair cell regeneration: Stereological analyses of damage and recovery from a single high dose of gentamicin. Hear Res. 1995;92:17-29.
42. Tanyeri H, Lopez J, Honrubia V. Histological evidence for hair cell regeneration after ototoxic cell destruction with local application of gentamicin in the chinchilla crista ampullaris. Hear Res. 1995;89:194-202.
43. Forge A, Li L, Corwin JT, Nevill G. Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. Science. 1993;259:1616-1619.
44. Matz GJ. Aminoglycoside ototoxicity. Am J Otolaryngol. 1986;7:117-119.
45. Jackson GG, Arcieri G. Ototoxicity of gentamicin in man: A survey and controlled analysis of clinical experience in the United States. J Infect Dis. 1971;124(Suppl):S130-S137.
46. Lerner SA, Seligsohn R, Matz GJ. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med. 1977;62:919-923.
47. Treatman I, Parsons J, Santoro J, et al. Pharmacology and efficacy of netilmicin. Antimicrob Agents Chemother. 1978;13:832-836.
48. Gialdroni Grassi G. The place of tobramycin in lower respiratory tract infections. J Chemother. 1995;7:344-354.
49. Periti P. La tobramicina - farmacologia clinica e chemoterapia. J Chemother. 1996; 8(Suppl 1):3-30.
50. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621-1629.
51. Levine DP, Crane LR, Zervos MJ. Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: A prospective comparative study. Rev Infect Dis. 1986;8:374-396.
52. Crane LR, Levine DP, Zervos MJ, Cummings G. Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev Infect Dis. 1986;8:364-373.
53. Reyes MP, Brown WJ, Lerner AM. Treatment of patients with Pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. Medicine (Baltimore). 1978;57:57-67.
54. Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis. 1983;5:314-321.
55. Rybak MJ, Boike SC, Levine DP, Erickson SR. Clinical use and toxicity of high-dose tobramycin in patients with Pseudomonal endocarditis. J Antimicrob Chemother. 1986; 17:115-120.
56. Tablan OC, Reyes MP, Rintelmann WF, Lerner AM. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in Pseudomonas endocarditis. J Infect Dis. 1984;149:257-263.
57. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. NEJM. 1993;328:1740-1746.
58. Odio W, van Laer E, Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol. 1975;15:518-524.
59. Wong GA, Pierce TH, Goldstein E, Hoeprich PD. Penetration of antimicrobial agents into bronchial secretions. Am J Med. 1975;59:219-223.
60. McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: Effect of dosage and concentration of antibiotic in sputum. J Infect Dis. 1976;134(Suppl):S191-S193.
61. Hall WH, Gerding DN, Schierl EA. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. J Infect Dis. 1977;135:957-961.
62. Dull WL, Alexander MR, Kasik JE. Bronchial secretion levels of amikacin. Antimierob Agents Chemother. 1979;16:767-771.
63. Alexander MR, Berglund EM, Kasik JE, et al. The concentration of tobramycin in bronchial secretions. Chest. 1979;75:675-678.
64. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7:42-48.
65. Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamycin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981;2:1137-1139.
66. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987;81:272-279.
67. Steinkamp G, Tümmler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989;6:91-98.
68. Wall MA, Terry AB, Eisenberg J, et al. Inhaled antibiotics in cystic fibrosis. Lancet. 1983;1:1325. Letter.
69. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J. 1984;20:43-45.
70. Nathanson I, Kropp GJA, Phillip L, Neter E. Effectiveness of aerosolized gentamicin in cystic fibrosis. Presented at the 26th annual meeting of the Cystic Fibrosis Foundation; May 16-17, 1985; Anaheim, Calif. Abstract.
71. Carswell F, Ward C, Cook DA, Speller DCE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest. 1987;81:356-360.
72. Wang C, Rolden MA, Aufderheide M, et al. The effect of tobramycin therapy in CF. Presented at the 25th annual meeting of the Cystic Fibrosis Foundation; April 27-30, 1984; San Jose, Calif. Abstract.
73. Franz MN, Spohn WA, Ronald PM. Evaluation of aerosol tobramycin therapy in CF. Presented at the 26th annual meeting of the Cystic Fibrosis Foundation; May 16-17, 1985; Anaheim, Calif. Abstract.
74. Jenkins SG, Kelly WC, Mason WG, et al. Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. Presented at the 26th annual meeting of the Cystic Fibrosis Foundation; May 16-17, 1985; Anaheim, Calif. Abstract.
75. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7:265-271.
76. Newman SP, Woodman G, Clarke SW. Deposition of carbenicillin aerosols in cystic fibrosis: Effects of nebuliser system and breathing pattern. Thorax. 1988;43:318-322.
77. Hoff GE, Schiotz PO, Paulsen J. Tobramycin treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Scand J Infect Dis. 1974;6:333-337.
78. MacLusky IB, Levinson H, Gold R, McLaughen FJ. Inhaled antibiotics in cystic fibrosis: Is there a therapeutic effect? J Pediatr. 1986;108:861-865.
79. Brown RB, Kruse JA, Counts GW, et al. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother. 1990;34:269-272.
80. Wallace SM, Chan L-Y. In vitro interaction of aminoglycosides with beta-lactam penicillins. Antimicrob Agents Chemother. 1985;28:274-281.
81. Glew RH, Pavuk RA. Stability of gentamicin, tobramycin, and amikacin in combination with four β-lactam antibiotics. Antimicrob Agents Chemother. 1983;24:474-477.
82. Halstenson CE, Wong MO, Herman CS, et al. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother. 1992;36:1832-1836.
83. Kradjan WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med. 1980;140:1668-1670.
84. Ervin FR, Bullock WE, Nuttall CE. Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother. 1976;9:1004-1011.
85. Halstenson CE, Hirata CA, Heim-Duthoy KL, et al. Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease. Antimicrob Agents Chemother. 1990;34:128-133.
86. Mclaughlin JE, Reeves DS. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. Lancet. 1971;1:261-264.
87. Nebcin® (Tobramycin) Product Information. Physicians' Desk Reference®. 52nd ed. Montvale, NJ: Medical Economics Data Production Company; 1998:1490-1492.
88. Sanford JP, Gilbert DN, Gerberding JL, Sande MA. Guide to Antimicrobial Therapy. Dallas: Antimicrobial Therapy Inc., 1994:103.
89. McCracken GH, Freij BJ. Clinical pharmacology of antimicrobial agents. In: Reminton JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant. 3rd ed. Philadelphia: WB Saunders; 1990:1020-1076.
90. Prober CG, Stevenson DK, Benitz WSE. The use of antibiotics in neonates weighing less than 1200 gm. Pediatr Infect Dis J. 1990;9:111-121.
91. Klein JO. Antimicrobial agents. In: Feign RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 3rd ed. Philadelphia: WB Saunders; 1992:2179-2198.
92. Zebner R, Quinn JP. Antimicrobials in cystic fibrosis: Emergence of resistance and implications for treatment. Semin Respir Infect. 1992;7:210-217.
93. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis. 1983;147:918-923.
94. Mukhopadhyay S, Baer S, Blanshard J, et al. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. J Antimicrob Chemother. 1993;31:429-436.
95. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs. 1994;47:902-913.
96. Ristuccia AM, Cunha BA. The aminoglycosides. Med Clin North Am. 1982;66:303-312.
97. Schentag JJ, Lasezkay G, Cumbo TJ, et al. Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother. 1978;13:649-656.
98. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994;27:32-48.
99. Follath F, Wenk M, Vozeh S. Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother. 1981;8(Suppl A):37-43.
100. Kahlmeter G, Hallberg T, Kamme C. Gentamicin and tobramycin in patients with various infections: Concentrations in serum and urinary excretion. J Antimicrob Chemother. 1978;4(Suppl A):37-45.
101. Bertino JS, Rotschafer JC. Editorial response: Single daily dosing of aminoglycosides - a concept whose time has not yet come. Clin Infect Dis. 1997;24:820-823.
102. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ. 1996;312:338-345.
103. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663.
104. Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health-Syst Pharm. 1996;53:1141-1150.
105. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786-795.
106. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809.
107. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review. Clin Infect Dis. 1997;24:810-815.
108. Nicolau DP, Freeman CD, Bellieveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
109. Gilbert DN. Editorial response: Meta-analyses are no longer required for determining the efficacy of single-daily-dosing of aminoglycosides. Clin Infect Dis. 1997;24:816-819.
110. Parker SE, Davey PG. Once-daily aminoglycoside dosing. Lancet. 1993;341:346-347.
111. Bergeron MG. What preclinical data are needed to justify once daily therapy? J Clin Pharmacol. 1992;32:698-705.
112. Levison ME. New dosing regimens for aminoglycoside antibiotics. Ann Intern Med. 1992;117:693-694.
113. Herscovici L, Grise G, Thauvin C, et al. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis. 1988;20:205-212.
114. Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single, large daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis. 1988;158:7-12.
115. Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988;158:13-22.
116. Craig WA, Leggett J, Totsuku H, Vogelmann B. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. J Drug Dev. 1988;1(Suppl 3):7-15.
117. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother. 1994;33:937-947.
118. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis. 1990;162:408-413.
119. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis. 1990;162:414-420.
120. Freeman CD, Strayer AH. Mega analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy. 1996;16:1093-1102.
121. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med. 1996;124:717-725.
122. Galløe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995;48:39-43.
123. Preston SL, Briceland LL. Reviews of therapeutics. Single daily dosing of aminoglycosides. Pharmacotherapy. 1995;15:297-316.
124. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol. 1995;39: 597-603.
125. Periti P. Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. J Chemother. 1995;7:311-337.
126. Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 1996;37:1040-1042.
127. Koo J, Tight R, Rajkumar V, Hawa Z. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med. 1996;101:177-183.
128. Grassi C, Ginesu F, Pozzi E, et al. Once daily tobramycin therapy in lower respiratory tract infections. J Chemother. 1995;7:371-379.
129. Okpara AU, Amaya-Diaz A, Egbunike IG, et al. Evaluating once daily dosing of aminoglycosides: An observational study. Formulary. 1996;31:34-48.
130. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 1995;14:1029-1038.
131. ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycosides plus β-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990;89:58-66.
132. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993;341:335-359.
133. van der Auwera P, Meunier F, Ibrahim S, et al. Pharmacodynamic parameters and toxicity of netilmicin (6 mg/kg/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991;35:640-647.
134. Ibrahim S, Derde MP, Kaufman L, et al. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Renal Fail. 1990;12:199-203.
135. Tulkens PM, Clerckx-Braun F, Donnz J, et al. Safety and efficacy of aminoglycosides once-a-day: Experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev. 1988;1:71-82.
136. Ahkee S, Smith R, Ritter GW, et al. Once-daily aminoglycoside dosing in lower respiratory tract infections. PT. 1995;20:226-234.
137. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991;27(Suppl C):41-47.
138. Rotschafer JC, Rybak MJ. Single daily dosing of aminoglycosides: A commentary. Ann Pharmacother. 1994;28:797-801.
139. Issell BF, Keating MJ, Valdivieso M, Bodey GP. Continuous infusion tobramycin combined with carbenicillin for infection in cancer patients. Am J Med Sci. 1979;277:311-318.
140. Bodey GP, Chang HY, Rodriguez V, Stewart D. Feasibility of administering aminoglycoside antibiotics by continuous infusion. Antimicrob Agents Chemother. 1975;8:328-333.
141. Vanhaeverbeek M, Siska G, Herchuelz A. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemother. 1993;31:185-187.
142. Bint AJ, Rees JC. The aminoglycosides revisited. Care Crit Ill. 1996;12:97-100.
143. Anon. Should aminoglycosides routinely be prescribed once daily? Drugs Ther Perspect. 1995;6:7-11.
144. Parker SE, Davey PG. Once-daily aminoglycoside administration in gram-negative sepsis: Economic and practical aspects. PharmacoEconomics. 1995;7:393-402.
145. Prins JM, Koopmans RP, Büller HR, et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis. 1995;14:531-535.
146. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Aust. 1990;153:516-518.
147. Nicolau DP, Wu AH, Finocchiaro S, et al. Once daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit. 1996;18:263-266.
148. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. PharmacoEconomics. 1996;10:494-503.
149. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605-609.
150. Lode H, Schaberg T, Kemmerich B, Stahlmann R. Neuere aspekte zur dosierung von aminoglykosidantibiotika. Chemother J. 1996;5:67-70.
151. Medicus-Bringa M, Ward G, Rice M. Once-daily versus pharmacokinetic dosing of aminoglycosides. Am J Med. 1997;103:328. Letter.